AFM13 – Trial open at LINEAR

The AMF13 trial has now been activated at LINEAR research institute

As a type of immunotherapy, AFM13 does not kill cancer cells directly but encourages the body’s own immune system to seek out and destroy the cells. It works by activating a type of immune cell, called a natural killer (NK) cell, and directing them to destroy the cancerous cells which harbour CD30, a molecule seen commonly on T-cell lymphoma cancer cells.

When the natural killer cell is linked to the cancerous cell by AFM13 binding, its cell-killing ability is activated. This results in the body’s own immune cells destroying the cancer in a targeted manner.

For further details on the trial, visit our Trials page on our website:

Trina’s greatest SHAVE!

Help Trina reach her $2000 goal!

On 13th March 2020, dedicated Sir Charles Gairdner Hospital Haematology Clinical Trial nurse, Trina, is SHAVING her hair in the leukaemia foundation’s Worlds Greatest Shave!!

Trina has been caring for cancer patients for 11 years. She has seen first hand how the leukaemia foundation can provide much needed emotional & physical support during those times of need.

Now Trina needs YOUR help to reach her goal. Every $ counts! 💙🧡

To read more about Trina’s story and to DONATE, visit:…/FundraisingPage…

 #wordsgreatestshave #leukaemiafoundation #bloodcancer #cancernurse #dedication #sircharlesgairdnerhospital #westernaustralia

Grant Funding awarded to Dr Carolyn Grove & Dr Xuan Tan

Congratulations to Dr Carolyn Grove, WA Senior Lecturer and Clinical & Laboratory Haematologist, and Dr Xuan Tan,  WA Haematology Research Fellow, who have been awarded grant funding by WA Health’s Research Translational Project scheme to conduct a Research project “Next Generation Sequencing in Chronic Lymphocytic Leukaemia and Acute Myeloid Leukaemia; A Health economic analysis”

Next generation sequencing (NGS) enables researchers to analyse genetics/DNA at a never-before seen level.

Dr Grove & Dr Tan’s project aims to analyse patients with newly diagnosed Chronic Lymphocytic Leukaemia and Acute Myeloid Leukaemia, to identify those patients who carry a genetic mutation; non-deletional TP53 mutation. NGS will be carried out on patients prior to treatment, to asses risk factors and aid treatment decisions (as patients with this particular genetic mutation often don’t do well with standard chemo-immunotherapy). The intended outcome of this analysis is to help form a business case to include next generation sequencing in haematological malignancies to assist with improved prognostication and improving treatment selection, in particular avoiding futile treatment which carries significant side effects for patients

A.Prof Cheah interviewed about aggressive lymphoma at global haematology event

ASH December 2019

Associate Professor Chan Cheah attended the annual ASH (American Society of Haematology) meeting in Dec 19. This global event, in malignant and non-malignant hematology, sees specialists from around the world attend and present on new and upcoming findings. Lymphoma Australia  interviewed A.Prof Cheah and you can find the first interview, on aggressive lymphoma here:


#bloodcancerresearchwa #BCRWA #haematology #westernaustralia #ASH2019 #lymphoma 

BCRWA 2019… what a spectacular first year!

As 2019 draws to a close, Blood Cancer Research WA (BCRWA) reflect on what a spectacular year we have had in Western Australia.

BCRWA has seen its FIRST fully-functioning year and what a difference it has already made to blood cancer patients by providing them with hope by being able to access Clinical Trials:

  • 21 haematology clinical trials are now currently open for patients in WA, compared to NINE in 2018 (as BCRWA launched)
  • 1st ever haematology clinical trial opened at Hollywood and has recruited NINE patients with AML (Acute Myeloid Leukaemia)
  • 57 patients have been recruited onto NINE clinical trials at LINEAR Clinical Research. Compared to ZERO before BCRWA began
  • 280 blood cancer patients are currently on clinical trials thanks to BCRWA!


2019 has been the greatest start to Blood Cancer Research WA that we could have wished for. We cannot wait to see what is achieved in 2020!!


Introducing our newest BCRWA member – Andrea

In collaboration with Snowdome Foundation, Blood Cancer Research WA are delighted to welcome our newest member of the team: Andrea Dawber


“It is a privilege and honour to join such a dynamic, dedicated team who are committed to making a difference to Australian blood cancer patients.”  Andrea is inspired and energised by the work of Assoc. Professor Chan Cheah and his vision for WA blood cancer patients. Andrea has already been very busy ‘making hope real’ for WA blood cancer patients.  We can’t wait to see Blood Cancer Research WA go from strength to strength”.


Andrea is a wonderful addition to our amazing Foundation. BCRWA are very excited for the future and for all of the hope we shall bring together.

Blood, Sweat and Tears of Joy in Western Australia

On 24th October 2019, the Snowdome Foundation and Blood Cancer Research WA hosted ‘Blood, Sweat and Tears of Joy’ an educational evening bringing together clinicians, researchers, patients and supporters.

The premise behind Blood Cancer Research WA was to bring blood cancer clinical trials to Western Australian patients.  Associate Professor Chan Cheah highlighted just how successful this endeavour has been with the number of patients enrolled into trials increasing by almost 100.  It makes your heart sing to know so many more blood cancer patients are now being offered a chance at another treatment.  Research shows that patients have better outcomes when they are part of trial and for many it is the only way to access new treatments.    Dr Katharine Lewis, Linear Fellow, added weight to this commenting that her role is funded for 2 years to ensure equity of access to new treatments in development.

Patient, Dave Crispin spoke of the hope he has been offered through a clinical trial.  Dave had exhausted all other treatment options when he was enrolled into a clinical trial for his follicular lymphoma.  He is currently on his second trial and his disease is under control.  He marvelled at the fact that the treatment he is currently on was not even in development when he was first diagnosed 7 years ago and he wonders what the future will hold.

Looking into the future and the latest advance in blood cancer treatment was guest speaker Dr Michael Dickinson from the Peter MacCallum Cancer Centre.  Michael has been heavily involved in the administration, preparation and management of patients receiving CAR T-cell therapy.  While the treatment is currently approved for use in paediatric and young adult B-cell precursor acute lymphoblastic leukaemia (ALL) and adult diffuse large B-cell lymphoma it is only funded by the government for ALL.  Michael explained how the treatment worked and the hope for the future, he emphasised that access through clinical trials is important especially for blood cancers where CAR T-cell therapy is currently not approved for use.

Adding to the lively panel discussion and interactive question and answer session were Prof Wendy Erber, and Dr Belinda Guo.  Both spoke passionately about in the importance of the right diagnosis and how genomics can aid not only diagnosis but also best treatment options for a patient based on their genetic profile.

The evening highlighted how your donation can ‘make hope real’ for West Australians with blood cancer – hope for remission; hope for less toxic treatments; hope for more time; hope for a cure and hope for the future.  So please donate to Snowdome Foundation to bring more trials, more hope and every opportunity of a cure to Western Australian blood cancer patients.

Our special thanks to the University Western Australia for hosting us in the IQX building and their delicious catering, as well as Rosabrook and Calneggia for providing the Prosecco and wines.

*Left-right: David Crispin, Dr Katharine Lewis, A/Prof Chan Cheah, Prof Wendy Erber, Dr Michael Dickinson and Dr Belinda Guo

[Blood Cancer Research WA would like to thank Snowdome Foundation for writing this beautiful article on our successful evening in Western Australia]


An exciting day for Dr Chan Cheah and his patient

What an exciting day it was yesterday for Dr Chan Cheah and his patient Robert, who is the very first patient on Dr Cheah’s own clinical trial LEVERAGE.

Dr Cheah has spent a few years designing the clinical trial, which will help treat patients with follicular lymphoma who are yet to receive any treatment for their blood cancer (treatment-naive).

The trial opened in Sept 2019 and is currently recruiting patients. Please visit: for further information



#clinicaltrial #LEVERAGE #bloodcancer #follicularlymphoma #BCRWA

A new trial for Follicular Lymphoma patients is trialing a combination of three drugs, in place of chemotherapy

An exciting new trial is open at Sir Charles Gairdner Hospital for patients with treatment-naïve Follicular Lymphoma: “LEVERAGE”

Follicular lymphoma is a common type of lymphoma, with thousands of West Australians each year living with the disease.

Associate Professor Chan Cheah, Consultant Haematologist in WA, has designed a new Clinical Trial which will see the evaluation of a novel combination of three drugs, in place of chemotherapy (the existing standard treatment).

This combination of treatments is designed to harness the immune system to target cancer cells, as well as priming them for self-destruction. The treatment is expected to be highly effective based and fewer side effects (such as hair loss, nerve damage and infections) compared with standard treatment, chemotherapy.



Visit our website for further information & contact details for the trial:

The first trial is available for EBV positive lymphoma patients

The Australasian Leukaemia and Lymphoma Group are the Sponsors of a new trial for Epstein Barr Virus (EBV) positive lymphoma patients, which will be recruiting at Sir Charles Gairdner Hospital:

Trebl-1 (NHL31)


Lymphomas that are associated with viruses can be difficult to treat. Until now there are no treatments available that specifically target EBV.

The new treatment is a combination of ibrutinib, rituximab, valaciclovir, and 3rd Party EBV-specific T cells (a type of white blood cell).

It is hoped this research will demonstrate that the infusions, in combination with ibrutinib, will be a safe and effective therapy for EBV positive lymphoma patients.

Visit: for further information